|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CEMIP |
Gene summary for CEMIP |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CEMIP | Gene ID | 57214 |
| Gene name | cell migration inducing hyaluronidase 1 | |
| Gene Alias | CCSP1 | |
| Cytomap | 15q25.1 | |
| Gene Type | protein-coding | GO ID | GO:0001932 | UniProtAcc | Q8WUJ3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 57214 | CEMIP | CCI_1 | Human | Cervix | CC | 1.66e-04 | 5.97e-01 | 0.528 |
| 57214 | CEMIP | CCI_2 | Human | Cervix | CC | 2.71e-03 | 4.86e-01 | 0.5249 |
| 57214 | CEMIP | CCI_3 | Human | Cervix | CC | 2.81e-03 | 2.71e-01 | 0.516 |
| 57214 | CEMIP | CCII_1 | Human | Cervix | CC | 2.68e-07 | 3.29e-01 | 0.3249 |
| 57214 | CEMIP | HTA11_3410_2000001011 | Human | Colorectum | AD | 5.76e-16 | 6.60e-01 | 0.0155 |
| 57214 | CEMIP | HTA11_2951_2000001011 | Human | Colorectum | AD | 6.57e-04 | 7.14e-01 | 0.0216 |
| 57214 | CEMIP | HTA11_1938_2000001011 | Human | Colorectum | AD | 2.54e-37 | 1.66e+00 | -0.0811 |
| 57214 | CEMIP | HTA11_78_2000001011 | Human | Colorectum | AD | 7.83e-07 | 8.31e-01 | -0.1088 |
| 57214 | CEMIP | HTA11_696_2000001011 | Human | Colorectum | AD | 5.31e-03 | 3.65e-01 | -0.1464 |
| 57214 | CEMIP | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.13e-24 | 1.46e+00 | -0.059 |
| 57214 | CEMIP | HTA11_866_3004761011 | Human | Colorectum | AD | 1.55e-11 | 6.02e-01 | 0.096 |
| 57214 | CEMIP | HTA11_10711_2000001011 | Human | Colorectum | AD | 1.24e-21 | 1.49e+00 | 0.0338 |
| 57214 | CEMIP | HTA11_7696_3000711011 | Human | Colorectum | AD | 8.35e-33 | 1.16e+00 | 0.0674 |
| 57214 | CEMIP | HTA11_6818_2000001011 | Human | Colorectum | AD | 1.44e-03 | 6.26e-01 | 0.0112 |
| 57214 | CEMIP | HTA11_6818_2000001021 | Human | Colorectum | AD | 1.01e-27 | 1.34e+00 | 0.0588 |
| 57214 | CEMIP | HTA11_99999970781_79442 | Human | Colorectum | MSS | 2.28e-34 | 7.97e-01 | 0.294 |
| 57214 | CEMIP | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 1.08e-06 | 1.47e+00 | 0.3487 |
| 57214 | CEMIP | HTA11_99999965104_69814 | Human | Colorectum | MSS | 8.79e-10 | 7.02e-01 | 0.281 |
| 57214 | CEMIP | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.30e-42 | 1.24e+00 | 0.3859 |
| 57214 | CEMIP | HTA11_99999973899_84307 | Human | Colorectum | MSS | 4.22e-02 | 4.32e-01 | 0.2585 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:190382910 | Cervix | CC | positive regulation of cellular protein localization | 72/2311 | 276/18723 | 3.20e-10 | 4.46e-08 | 72 |
| GO:00512359 | Cervix | CC | maintenance of location | 78/2311 | 327/18723 | 5.18e-09 | 4.92e-07 | 78 |
| GO:003367410 | Cervix | CC | positive regulation of kinase activity | 101/2311 | 467/18723 | 8.66e-09 | 7.22e-07 | 101 |
| GO:005122210 | Cervix | CC | positive regulation of protein transport | 72/2311 | 303/18723 | 2.36e-08 | 1.70e-06 | 72 |
| GO:00458608 | Cervix | CC | positive regulation of protein kinase activity | 85/2311 | 386/18723 | 5.61e-08 | 3.29e-06 | 85 |
| GO:005165110 | Cervix | CC | maintenance of location in cell | 55/2311 | 214/18723 | 6.63e-08 | 3.85e-06 | 55 |
| GO:190495110 | Cervix | CC | positive regulation of establishment of protein localization | 73/2311 | 319/18723 | 9.69e-08 | 5.25e-06 | 73 |
| GO:000660510 | Cervix | CC | protein targeting | 68/2311 | 314/18723 | 2.17e-06 | 6.55e-05 | 68 |
| GO:00719007 | Cervix | CC | regulation of protein serine/threonine kinase activity | 75/2311 | 359/18723 | 2.76e-06 | 8.02e-05 | 75 |
| GO:00903167 | Cervix | CC | positive regulation of intracellular protein transport | 41/2311 | 160/18723 | 3.24e-06 | 8.80e-05 | 41 |
| GO:00323868 | Cervix | CC | regulation of intracellular transport | 71/2311 | 337/18723 | 3.70e-06 | 9.74e-05 | 71 |
| GO:00331579 | Cervix | CC | regulation of intracellular protein transport | 52/2311 | 229/18723 | 8.16e-06 | 1.88e-04 | 52 |
| GO:00719025 | Cervix | CC | positive regulation of protein serine/threonine kinase activity | 46/2311 | 200/18723 | 1.87e-05 | 3.47e-04 | 46 |
| GO:19054778 | Cervix | CC | positive regulation of protein localization to membrane | 29/2311 | 106/18723 | 2.29e-05 | 4.01e-04 | 29 |
| GO:00323889 | Cervix | CC | positive regulation of intracellular transport | 46/2311 | 202/18723 | 2.45e-05 | 4.24e-04 | 46 |
| GO:00901509 | Cervix | CC | establishment of protein localization to membrane | 54/2311 | 260/18723 | 7.67e-05 | 1.05e-03 | 54 |
| GO:19054758 | Cervix | CC | regulation of protein localization to membrane | 36/2311 | 175/18723 | 1.33e-03 | 1.05e-02 | 36 |
| GO:00181076 | Cervix | CC | peptidyl-threonine phosphorylation | 25/2311 | 116/18723 | 3.59e-03 | 2.30e-02 | 25 |
| GO:19035334 | Cervix | CC | regulation of protein targeting | 19/2311 | 81/18723 | 3.96e-03 | 2.48e-02 | 19 |
| GO:00182106 | Cervix | CC | peptidyl-threonine modification | 26/2311 | 125/18723 | 4.98e-03 | 2.97e-02 | 26 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CEMIP | SNV | Missense_Mutation | novel | c.2495A>T | p.Glu832Val | p.E832V | Q8WUJ3 | protein_coding | deleterious(0.03) | possibly_damaging(0.617) | TCGA-3C-AALJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| CEMIP | SNV | Missense_Mutation | novel | c.1018G>T | p.Gly340Trp | p.G340W | Q8WUJ3 | protein_coding | tolerated(0.39) | benign(0.096) | TCGA-A7-A0DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
| CEMIP | SNV | Missense_Mutation | c.1352N>A | p.Ala451Glu | p.A451E | Q8WUJ3 | protein_coding | deleterious(0) | benign(0.422) | TCGA-A8-A08B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
| CEMIP | SNV | Missense_Mutation | c.2273N>T | p.Ser758Leu | p.S758L | Q8WUJ3 | protein_coding | deleterious(0.03) | benign(0.086) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CEMIP | SNV | Missense_Mutation | c.2552N>G | p.Asp851Gly | p.D851G | Q8WUJ3 | protein_coding | tolerated(0.56) | possibly_damaging(0.73) | TCGA-E2-A1B0-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD | |
| CEMIP | deletion | Frame_Shift_Del | rs779771025 | c.801delN | p.Pro268LeufsTer5 | p.P268Lfs*5 | Q8WUJ3 | protein_coding | TCGA-A2-A0T5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Taxotere | SD | ||
| CEMIP | insertion | Nonsense_Mutation | novel | c.756_757insGATTCTAAGATGCATTATCATAAGAATCATTAACAGGTCAAT | p.Met252_Thr253insAspSerLysMetHisTyrHisLysAsnHisTerGlnValAsn | p.M252_T253insDSKMHYHKNH*QVN | Q8WUJ3 | protein_coding | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| CEMIP | insertion | Frame_Shift_Ins | novel | c.304_305insCTCCTCTCTTCCATGGGAATGGTCCTGGCAGCCTTCC | p.Asp102AlafsTer40 | p.D102Afs*40 | Q8WUJ3 | protein_coding | TCGA-AN-A0FK-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
| CEMIP | insertion | Frame_Shift_Ins | novel | c.2325_2326insTCTACTT | p.Arg776SerfsTer37 | p.R776Sfs*37 | Q8WUJ3 | protein_coding | TCGA-BH-A0EE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | SD | ||
| CEMIP | deletion | Frame_Shift_Del | novel | c.3580delN | p.Pro1194ArgfsTer11 | p.P1194Rfs*11 | Q8WUJ3 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |